Adapting FAMS to Optimize CGM Use Among Emerging Adults With Type 1 Diabetes

The goal of this clinical trial is to evaluate the efficacy of an adapted FAMS (Family/friend Activation to Motivate Self-care) intervention on CGM use among study participants who are CGM users. We will leverage the infrastructure of an NIDDK-funded RCT evaluating FAMS-T1D among N=280 emerging adults with T1D who have elevated hemoglobin A1c or elevated diabetes distress (NCT05820477). We anticipate at least 50% using CGM to be included in these analyses.

Study Overview

• Status: Active, not recruiting
• Conditions: Type 1 Diabetes
• Intervention / Treatment: Behavioral: FAMS-T1D; Behavioral: Digital resources for diabetes

Detailed Description

FAMS (Family/friend Activation to Motivate Self-care) is a mobile phone-delivered intervention, based on Family Systems Theory, which helps adults with diabetes set behavioral goals and improve support received from friends and family for goal success. FAMS includes monthly phone coaching and text message support by FAMS coaches for the person with diabetes (PWD) and the option to enroll a support person (SP) to receive automated texts tailored to the self-care goals the person with T1D sets in coaching sessions. Adaptations specific to CGM include the option to set CGM use goals in coaching (and receive associated text support) and skill-building exercises during coaching to support data sharing relationships (e.g., establishing, setting and adjusting ground rules about communication).

Within the FAMS-T1D RCT (NCT05820477), we will test effects of FAMS-T1D on CGM use use relative to enhanced treatment as usual. We will evaluate effects on CGM use from baseline to post-intervention (6 months) as the primary endpoint. Study start date for the nested trial (NCT05854069) is the enrollment date of the first participant using a CGM. Since the goal of this trial is to assess effects of the adapted FAMS intervention on CGM use, the date participant CGM usage was confirmed is considered the enrollment date.

• Study Type: Interventional
• Enrollment (Estimated): 140
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • California
    • Los Angeles, California, United States, 90027
      • Children's Hospital of Los Angeles
  • Utah
    • Salt Lake City, Utah, United States, 84112
      • University of Utah

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

PERSONS WITH DIABETES

• Ages 18-24
• Have a diagnosis of T1D and has been taking insulin for at least one year
• Comfortable sending and receiving texts
• Can speak, read, and write in English
• Meets one of the following two criteria: 1) has a most recent A1c value in the EHR that is 7.5% or higher (or missing) OR 2) screen positive for diabetes distress on the two-item Diabetes Distress Screen (DDS-2)
• Using a continuous glucose monitor (CGM)

SUPPORT PERSONS

• Age 18 or older
• Can speak, read, and write in English or Spanish
• Comfortable sending and receiving texts

Exclusion Criteria:

PERSONS WITH DIABETES

• Has a condition that would prohibit study completion (intellectual disability, blindness or auditory limitations, severe mental illness)
• Plans to live outside the country during the study period

SUPPORT PERSONS

• Shares a phone with the person with diabetes
• Plans to live outside of the country during the study period

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Supportive Care
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: FAMS-T1D; Participants will receive FAMS-T1D components (monthly phone coaching and text message support for goals) for 6 months. Support persons will receive text messages that are tailored to the goal set by the person with type 1 diabetes. All persons with diabetes will receive text messages regarding how to access their HbA1c results and receive links providing information to assist them in self-care behaviors related to their diabetes. All support persons will also receive materials about type 1 diabetes and how to provide helpful support to the person with diabetes.	Behavioral: FAMS-T1D; FAMS-T1D involves monthly phone coaching that assists individuals in setting specific and time bound diabetes goals with automated text message support to the patient participant and less frequent automated text messages to their support person, if one is enrolled. Behavioral: Diabetes Resources High quality digital materials about diabetes management will be provided upon enrollment and send to participants quarterly.; Other Names: Family/friend Activation to Motivate Self-Care for those with Type 1 Diabetes; Behavioral: Digital resources for diabetes; Quality digital resources about diabetes management provided upon enrollment and during the study.
Placebo Comparator: Digital resources for diabetes; All persons with diabetes will receive text messages regarding how to access their HbA1c results and receive links providing information to assist them in self-care behaviors related to their diabetes. All support persons will also receive materials about type 1 diabetes and how to provide helpful support to the person with diabetes.	Behavioral: Digital resources for diabetes; Quality digital resources about diabetes management provided upon enrollment and during the study.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
CGM frequency of use during the intervention period	Change in CGM frequency of use assessed by self-report on questionnaire; more frequent use/higher is better	Baseline and 6 months post-baseline
CGM frequency of use during the intervention period	Change in CGM frequency of use assessed by objective CGM data (% of time; higher is better)	Baseline and 6 months post-baseline
Gaps in CGM use	Length of gaps in CGM use as assessed by objective CGM data (measured in number of consecutive days without CGM data; higher is worse)	6 months post-baseline

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
CGM behavioral responses during the intervention period	Change in frequency of making behavioral changes in response to CGM data assessed by self-report; higher scores indicate more frequent response (better)	Baseline and 6 months post-baseline
Barriers to CGM use during the intervention period	Change in perceived influence of CGM on glycemic control scale assessed by Glucose Monitoring Survey; higher scores indicate more perceived problems with CGM use (worse)	Baseline and 6 months post-baseline
Barriers to CGM use during the intervention period	Change in perceived influence of CGM on social complications assessed by Glucose Monitoring Survey; higher scores indicate more perceived problems with CGM use (worse)	Baseline and 6 months post-baseline
CGM satisfaction during the intervention period	Change in CGM satisfaction assessed by Benefits of CGM scale; higher scores indicate more perceived benefits of CGM use (better)	Baseline and 6 months post-baseline

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Data sharing during the intervention period	Number of data sharing relationships, between groups; more is better	6 months post-baseline
Satisfaction with data-sharing relationships	Satisfaction with data-sharing relationships assessed by CGM-Satisfaction Scale; higher scores are better	6 months post-baseline

Collaborators and Investigators

• Sponsor: Vanderbilt University Medical Center
• Collaborators: University of Utah; Children's Hospital Los Angeles; The Leona M. and Harry B. Helmsley Charitable Trust; University of California, Merced

Study record dates

Study Major Dates

• Study Start (Actual): April 30, 2023
• Primary Completion (Estimated): January 31, 2027
• Study Completion (Estimated): April 30, 2027

Study Registration Dates

• First Submitted: April 24, 2023
• First Submitted That Met QC Criteria: May 9, 2023
• First Posted (Actual): May 11, 2023

Study Record Updates

• Last Update Posted (Estimated): October 29, 2025
• Last Update Submitted That Met QC Criteria: October 27, 2025
• Last Verified: October 1, 2025

More Information

Terms related to this study

• Keywords: Emerging adults; Mobile health; Social support; Diabetes distress; Time in range; Hemoglobin A1c; Continuous glucose monitor; Text message; Family support; Goal setting
• Additional Relevant MeSH Terms: Endocrine System Diseases; Metabolic Diseases; Autoimmune Diseases; Immune System Diseases; Glucose Metabolism Disorders; Diabetes Mellitus; Nutritional and Metabolic Diseases; Diabetes Mellitus, Type 1
• Other Study ID Numbers: 220847; G-2203-05822 (Other Grant/Funding Number: The Leona M. and Harry B. Helmsley Charitable Trust)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: After study results are posted on clinical trials and published, de-identified data will be available upon requests made to the principal investigator.
• IPD Sharing Time Frame: After study results are posted on clinical trials and outcomes published in a peer-reviewed journal, until 5 years later.
• IPD Sharing Access Criteria: Contact the principal investigator
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ICF

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No